Paul Takam Kamga
Paul Takam Kamga
1
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France
1,
Aurélie Swalduz
Aurélie Swalduz
2
Department of Medical Oncology, Centre Léon Bérard, Lyon, France
3
Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
2,3,
Adrien Costantini
Adrien Costantini
1
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France
4
Department of Respiratory Diseases and Thoracic Oncology, APHP – Hopital Ambroise Pare, Boulogne-Billancourt, France
1,4,
Catherine Julié
Catherine Julié
1
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France
5
Department of Pathology, APHP – Hopital Ambroise Pare, Boulogne-Billancourt, France
1,5,
Jean-François Emile
Jean-François Emile
1
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France
1,
Maurice Pérol
Maurice Pérol
2
Department of Medical Oncology, Centre Léon Bérard, Lyon, France
2,
Virginie Avrillon
Virginie Avrillon
3
Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
3,
Sandra Ortiz-Cuaran
Sandra Ortiz-Cuaran
3
Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
3,
Pierre De Saintigny
Pierre De Saintigny
2
Department of Medical Oncology, Centre Léon Bérard, Lyon, France
3
Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
2,3,
Etienne Giroux-Leprieur
Etienne Giroux-Leprieur
1
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France
4
Department of Respiratory Diseases and Thoracic Oncology, APHP – Hopital Ambroise Pare, Boulogne-Billancourt, France
1,4,*
1
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France
2
Department of Medical Oncology, Centre Léon Bérard, Lyon, France
3
Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France
4
Department of Respiratory Diseases and Thoracic Oncology, APHP – Hopital Ambroise Pare, Boulogne-Billancourt, France
5
Department of Pathology, APHP – Hopital Ambroise Pare, Boulogne-Billancourt, France
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
✉*Correspondence: Etienne Giroux-Leprieur, Etienne.giroux-leprieur@aphp.fr
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
Received 2022 Jan 11; Accepted 2022 Jan 20; Collection date 2022.
Keywords: non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR), Sonic Hedgehog (Shh), biomarker, tyrosine kinase inhibitor (TKI)
Copyright © 2022 Takam Kamga, Swalduz, Costantini, Julié, Emile, Pérol, Avrillon, Ortiz-Cuaran, De Saintigny and Giroux-Leprieur
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.